Who is sponsoring NCT07068620?

NCT07068620 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT07068620?

Interventions in NCT07068620: Home-based cognitive training.

What condition does NCT07068620 study?

NCT07068620 studies Cerebral Small Vessel Disease, Stroke, Cognitive Complaint.

Is NCT07068620 still recruiting?

NCT07068620 is currently recruiting now. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT07068620: SHIVA-CogNeuro

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort. SHIVA-CogNeurophys

Recruiting now NA Last updated 2 February 2026

What this trial tests

NA trial testing Home-based cognitive training in Cerebral Small Vessel Disease in 80 participants. Currently enrolling.

Timeline

7 August 2025

Primary endpoint
7 March 2028

7 March 2028

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	80
Start date	7 August 2025
Primary completion	7 March 2028
Estimated completion	7 March 2028
Sites	1 location across France

Drugs / interventions tested

Home-based cognitive training

Conditions studied

Cerebral Small Vessel Disease — all drugs for Cerebral Small Vessel Disease →
Stroke — all drugs for Stroke →
Cognitive Complaint — all drugs for Cognitive Complaint →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Cerebral Small Vessel Disease or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral small vessel disease (cSVD) is characterized by an alteration of the structure and function of small penetrating brain arteries. Highly prevalent in older individuals from the general population, it represents a leading cause of stroke and a major contributor to cognitive decline and risk of dementia. Better detection and management of covert cSVD would have a major impact on preventing disability and costs related to stroke, cognitive impairment and dementia. The aim of the present study is to identify novel electroencephalographic (EEG) biomarkers of the cognitive deficits associated with cSVD, and how these biomarkers and cognitive performance are affected by personalized cognitive training or transcranial alternating current stimulation (tACS), a non-invasvie brain stimulation technique.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cerebral Small Vessel Disease

Currently open trials in the same condition.

NCT06674460 — Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease · Phase 3 · recruiting
NCT05715710 — Correlation Between Deep Medullary Veins and Cognitive Dysfunction in Cerebral Small Vessel Disease · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07068620 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07068620.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing